predicted severe acute pancreatitis
Conditions
Interventions
treatment group:conventional treatment+octreotide+parecoxib/celecoxib
control group:conventional treatment+octreotide
Sponsors
Department of Gastroenterology, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as acute pancreatitis having two of the following three features: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum amylase or lipase activity increased at least three times greater than the upper limit of normal, and 3. characteristic ?ndings of acute pancreatitis on transabdominal ultrasonography and computed tomography (CT)or magnetic resonance imaging (MRI). 2. APACHE II score more than 8; 3. admission within 48h from the onset of symptoms; 4. patients did not receive any NSAIDS, somatostatin and its analogue one month before admission; 5. age older than 18 years old; 6. patients voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients hypersensitive to sulfonamides; 2. women in pregnancy or lactation; 3. patients with severe diseases of heart, lung, brain and kidnery, and patients with other severe diseases of the digestive system, such as cirrhosis, esophageal varices, peptic ulcer, alimentary tract hemorrhage in recent one month, ulcerative colitis, Crohn's disease and malignant tumors; 4. patients with drug abuse, psychinosis et al.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of SAP; | — |
Secondary
| Measure | Time frame |
|---|---|
| time of start eating;fluid sequestration in the first 72 hours;plasma somatostatin concentration;fluid input before end-point;duration before end-poin;incidence of long-term complicatio;cost of hospitalization;length of hospital stay;Mortality;incidence of organ failure;OF score;CTSI;SIRS score;APACHE II score;the scores of abdominal pain;Consumption of pethidine;serum C-reaction protein (CRP);serum interleukin-6 (IL-6);serum tumor necrosis factor (IL-6); | — |
Countries
China
Contacts
Public ContactHuang Libin
Outcome results
None listed